financetom
Business
financetom
/
Business
/
Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says
Mar 11, 2026 2:47 AM

11:18 AM EST, 02/03/2026 (MT Newswires) -- Johnson & Johnson's ( JNJ ) solid financial position and robust fundamentals will likely mitigate the impact of the ongoing talc powder lawsuits against the company, RBC Capital Markets said in a note Tuesday.

RBC said that Johnson & Johnson ( JNJ ) will have the ability to spread risks linked to the talc litigation over time and may get more settlements, with the suits likely to "drag on for years" as the company "potentially litigates this case-by-case and year-by-year."

Additionally, the company has a "strong financial position with substantial cash on its balance sheet" with meaningful free cash flow generation annually, the note said.

Separately from the talc suits, RBC said the company is seeing "continued strong fundamentals" and its recent share price increase supports a "higher multiple on a modestly raised EPS estimate."

Many of Johnson & Johnson's ( JNJ ) catalysts are yet to play out aiding growth acceleration, the investment firm said.

RBC lifted Johnson & Johnson's ( JNJ ) price target to $255 from $240, while keeping the company's outperform rating.

Price: 233.22, Change: +2.47, Percent Change: +1.07

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AstraZeneca asthma drug more effective during attack than steroids, study finds
AstraZeneca asthma drug more effective during attack than steroids, study finds
Nov 27, 2024
LONDON, Nov 27 (Reuters) - AstraZeneca's ( AZN ) Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for further treatment by 30%, according to a study published on Wednesday. The antibody drug known chemically as benralizumab was approved by...
BlackRock has deal to buy private credit manager HPS, FT reports
BlackRock has deal to buy private credit manager HPS, FT reports
Nov 27, 2024
Nov 28 (Reuters) - BlackRock ( BLK ) has a handshake deal to buy private credit group HPS Investment Partners, the Financial Times reported on Wednesday. The final deal value would be closer to $12 billion, which offers a significant premium over HPS's post-IPO valuation of $10 billion, the report said, citing two sources familiar with the matter. The two...
BlackRock has deal to buy private credit manager HPS, FT reports
BlackRock has deal to buy private credit manager HPS, FT reports
Nov 27, 2024
Nov 28 (Reuters) - BlackRock ( BLK ) has a handshake deal to buy private credit group HPS Investment Partners, and the transaction for the lender could cost $12 billion, The Financial Times reported on Wednesday. The two sides have agreed on the broad outline of the deal with an eye towards announcing general terms after the U.S. Thanksgiving holiday,...
BRIEF-Scisparc Ltd Entered Into Second Addendum To Merger Agreement With Automax Motors Ltd And Scisparc Merger Sub Ltd
BRIEF-Scisparc Ltd Entered Into Second Addendum To Merger Agreement With Automax Motors Ltd And Scisparc Merger Sub Ltd
Nov 27, 2024
Nov 27 (Reuters) - Scisparc Ltd ( SPRC ): * SCISPARC LTD ( SPRC ): ENTERED INTO SECOND ADDENDUM TO MERGER AGREEMENT WITH AUTOMAX MOTORS LTD AND SCISPARC MERGER SUB LTD * SCISPARC LTD ( SPRC ): RIGHT TO TERMINATE MERGER AGREEMENT IF MERGER WAS NOT CONSUMMATED BY NOV 30, 2024, WAS DEFERRED TO MARCH 31, 2025 Source text: Further...
Copyright 2023-2026 - www.financetom.com All Rights Reserved